Home




LATEST NEWS

 
Moleac’s CEO, David Picard, presented on “E-Commerce: Going beyond the traditional visibility of Pharma Products” at the Pharmaceutical Congress Asia 2014

Our presence worldwide

map
Singapore (Headquarters) 11 Biopolis Way,Helios #09-07/08,  Singapore 138667 Beijing Office Room 1409, Zhong’anshengye Plaza, No.168 Beiyuan Road, Chaoyang District, Beijing 100101, P. R. China Moleac Europe 92 rue de la Victoire 75009,Paris France Moleac Poland 75/37 Kościuszki Street 30-105 Cracow,Poland

 
Today, our company has 40 employees with 13 nationalities. Its operations are done throughout several countries thanks to 3 offices: Moleac Singapore (headquarters), Moleac Europe and Poland and through exclusive partnerships

Moleac’s Multi-Modal Approach to Treatment for Brain Injuries

Advances in research in the field of brain injury, like stroke, trauma and global ischemia, has never been more exciting and encouraging for the prospect of discovering novel effective treatments.

The conventional approach to research in acute treatment to develop one molecule targeted at one specific process in the pathway of one particular disease has failed in many consecutive clinical trials. Moleac takes on a multi-model strategy in its approach to drug development.

What is Stroke?

video



Upcoming events

arrow

WSC – World Stroke Congress
22nd-25th October 2014 in Istanbul – Turkey
www2.kenes.com

Career Opportunities

 
If you are talented and ready for a new challenge, discover what Moleac has to offer you.

NeuroAiD

Moleac has brought to market the first drug that helps patients recover faster and better from their stroke disabilities.
 
NeuroAiD™ (MLC 601, MLC 901) addresses these gaps in pharmacological modalities which combined to a rehabilitation program offers new hopes to patients who had no other choice than to cope with their disabilities.

video